<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932096</url>
  </required_header>
  <id_info>
    <org_study_id>GPEDI1282A</org_study_id>
    <secondary_id>1K23HL150229-01A1</secondary_id>
    <nct_id>NCT04932096</nct_id>
  </id_info>
  <brief_title>Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin</brief_title>
  <acronym>SMARTKids</acronym>
  <official_title>Sleep Management And Recovery After Traumatic Brain Injury in Kids (SMARTKids): Evidence for Targeting Sleep to Improve Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep wake disturbances compound recovery in over half of pediatric traumatic brain injury&#xD;
      survivors, leading to impaired quality of life, and few effective interventions exist to&#xD;
      treat this important morbidity. Therefore, this study will conduct a randomized controlled&#xD;
      trial evaluating a melatonin and sleep management intervention started during hospitalization&#xD;
      and continued after discharge compared to standard care with placebo. The trial will&#xD;
      investigate if this intervention is feasible, acceptable, and effective at reducing sleep&#xD;
      wake disturbances as measured on the Sleep Disturbances Scale for Children 1-month after&#xD;
      hospital discharge.&#xD;
&#xD;
      Participants will be randomly assigned to receive the intervention (melatonin and sleep plan)&#xD;
      or to the control group (placebo with standard care) with a goal of equal numbers of&#xD;
      participants in each group. Participants will be followed closely after consent and outcomes&#xD;
      will be assessed at hospital discharge, 2-weeks, and 1-month. Outcomes will focus on&#xD;
      feasibility (ability to recruit patients into the trial) and acceptability (patient safety&#xD;
      and satisfaction), but will also assess the effectiveness of the intervention to reduce sleep&#xD;
      disturbances after discharge. The investigators will assess sleep using questionnaires and&#xD;
      actigraphy (watch-like activity monitors). Exploratory outcomes will include global health&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2022</start_date>
  <completion_date type="Anticipated">August 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep disturbance</measure>
    <time_frame>1-month</time_frame>
    <description>Sleep Disturbances Scale for Children: 26-item parent proxy sleep questionnaire with higher scores reflecting greater disturbance and risk for clinically important sleep disorders. Each question is scored 1 through 5 for a range of possible total scores of 26 - 130.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adherence quantitative</measure>
    <time_frame>1-month</time_frame>
    <description>pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adherence qualitative</measure>
    <time_frame>1-month</time_frame>
    <description>participant report of compliance with treatment regimen evaluated by survey question estimating percentage of study days compliant with intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>1-month</time_frame>
    <description>Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL MFS); 18 item parent proxy report of fatigue. Scores range 0-100 with higher scores indicating better function and less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronotype</measure>
    <time_frame>1-month</time_frame>
    <description>Children's Chronotype Questionnaire, 27 item parent reported survey of circadian rhythm characteristics. Each item assessed independently.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep latency</measure>
    <time_frame>1-month</time_frame>
    <description>actigraphy measured time in minutes to fall asleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total sleep time</measure>
    <time_frame>1-month</time_frame>
    <description>actigraphy measured total time asleep in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wake after sleep onset</measure>
    <time_frame>1-month</time_frame>
    <description>actigraphy measured time in minutes awake after sleep onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of night awakenings</measure>
    <time_frame>1-month</time_frame>
    <description>actigraphy measured number of instances awoken after sleep onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep efficiency</measure>
    <time_frame>1-month</time_frame>
    <description>actigraphy measure percentage of nighttime period spent asleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep onset</measure>
    <time_frame>1-month</time_frame>
    <description>time of day fell asleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep offset</measure>
    <time_frame>1-month</time_frame>
    <description>time of day waking from nighttime sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events time 0</measure>
    <time_frame>hospital discharge assessed up to 7 days</time_frame>
    <description>Evaluation of adverse events asking participants to report any side effects of study interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events time 1</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluation of adverse events asking participants to report any side effects of study interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events time 2</measure>
    <time_frame>1-month</time_frame>
    <description>Evaluation of adverse events asking participants to report any side effects of study interventions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>reason for non-adherence</measure>
    <time_frame>1-month</time_frame>
    <description>qualitative response to survey question about reasons for non-compliance with treatment regimen or sleep plan</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>1-month</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL): parent reported measure of quality of life. Scores range 0-100 with higher scores indicating better quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>cognitive functioning</measure>
    <time_frame>1-month</time_frame>
    <description>Behavior Rating Inventory of Executive Function, second edition (BRIEF-2); parent proxy report of everyday executive function, reported as standardized Global Executive Composite T-score, with higher scores indicating worse function. T-scores range from 0-100, with a mean of 50 and standard deviation of 10.</description>
  </other_outcome>
  <other_outcome>
    <measure>physical functioning</measure>
    <time_frame>1-month</time_frame>
    <description>Functional Status Scale, range 6-30, with higher scores indicating worse function</description>
  </other_outcome>
  <other_outcome>
    <measure>anxiety</measure>
    <time_frame>1-month</time_frame>
    <description>Patient Reported Outcome Measurement Information System (PROMIS) anxiety short form T-score with higher scores indicating worse outcome. T-scores range from 0 - 100, with a mean of 50 and standard deviation of 10.</description>
  </other_outcome>
  <other_outcome>
    <measure>depression</measure>
    <time_frame>1-month</time_frame>
    <description>Patient Reported Outcome Measurement Information System (PROMIS) depression short form T-score with higher scores indicating worse outcome. T-scores range from 0-100, with a mean of 50 and standard deviation of 10.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Critical Illness</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Melatonin and sleep plan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(melatonin doses of 1mg, 3mg, or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days) and sleep management plan based on patient age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>melatonin supplementation</description>
    <arm_group_label>Melatonin and sleep plan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>sleep management plan</intervention_name>
    <description>Participants randomized to the intervention will receive an age-based sleep management plan created from American Academy of Pediatrics and American Academy of Sleep Medicine guidelines for healthy sleep in children.</description>
    <arm_group_label>Melatonin and sleep plan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>cellulose filled capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Children age â‰¥6 years and &lt;19 years&#xD;
&#xD;
          -  Traumatic brain injury defined as disruption of the normal function of the brain&#xD;
             resulting from blunt force injury with a severity defined as mild complicated,&#xD;
             moderate, or severe by the Glasgow Coma Scale with the presence of intracranial injury&#xD;
             on imaging&#xD;
&#xD;
          -  Admission to Oregon Health &amp; Science University Hospitals&#xD;
&#xD;
          -  Deemed likely to survive hospitalization by clinical care team&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Lack stable means of communication with study team (phone, email, mailing address)&#xD;
&#xD;
          -  Abusive trauma suspected or confirmed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cydni Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cydni N Williams, MD</last_name>
    <phone>503-494-5522</phone>
    <email>willicyd@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Randall, BS</last_name>
    <phone>503-494-5522</phone>
    <email>randalj@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cydni Williams, MD</last_name>
      <phone>503-494-5522</phone>
      <email>willicyd@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Randall, BS</last_name>
      <phone>503-494-5522</phone>
      <email>randalj@ohsu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsu.edu/pncc</url>
    <description>Principal Investigator program website that will be updated regularly for PI contact information and study related materials</description>
  </link>
  <reference>
    <citation>Luther M, Poppert Cordts KM, Williams CN. Sleep disturbances after pediatric traumatic brain injury: a systematic review of prevalence, risk factors, and association with recovery. Sleep. 2020 Oct 13;43(10). pii: zsaa083. doi: 10.1093/sleep/zsaa083.</citation>
    <PMID>32328648</PMID>
  </reference>
  <reference>
    <citation>Poppert Cordts KM, Hall TA, Hartman ME, Luther M, Wagner A, Piantino J, Guilliams KP, Guerriero RM, Jara J, Williams CN. Sleep Measure Validation in a Pediatric Neurocritical Care Acquired Brain Injury Population. Neurocrit Care. 2020 Aug;33(1):196-206. doi: 10.1007/s12028-019-00883-5.</citation>
    <PMID>31797275</PMID>
  </reference>
  <reference>
    <citation>Williams CN, Hartman ME, McEvoy CT, Hall TA, Lim MM, Shea SA, Luther M, Guilliams KP, Guerriero RM, Bosworth CC, Piantino JA. Sleep-Wake Disturbances After Acquired Brain Injury in Children Surviving Critical Care. Pediatr Neurol. 2020 Feb;103:43-51. doi: 10.1016/j.pediatrneurol.2019.08.010. Epub 2019 Aug 26.</citation>
    <PMID>31735567</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Cydni Williams</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>melatonin</keyword>
  <keyword>sleep</keyword>
  <keyword>intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Basic tabular results will be entered into clinicaltrials.gov within 1 year of primary completion of the study. We will make participant data available to researchers once thoroughly de-identified and approved by our institutional review board within 1 year of study completion. Data will be made available on requests made directly to the Principal Investigator.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The study protocol and SAP will be shared upon approval by the Institutional Review Board, and the final approved study protocol and SAP with documentation of any amendments will be available at study completion. The ICF will be shared no later than 60days from enrollment of the last study visit. A CSR and analytic code for the primary outcomes analysis will be made available within 1 year of study completion.</ipd_time_frame>
    <ipd_access_criteria>Requests for data can be made by contacting the Principal Investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

